AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1973942
Drug: Gepirone (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone (continuation therapy after 6 weeks of open therapy)
Trial: 28740085
Drug: Alcohol self‐dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol self‐dosing
Trial: 19439989
Drug: Acetylcysteine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (5 g in 5% glucose in a final volume of 50 ml) administered intravenously during hemodialysis
Trial: 7714222
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day buspirone
Trial: 2655688
Drug: ICI 169,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169, 369 (10, 30, and 50 mg)
Trial: 29173304
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg/dose, 2 doses)
Trial: 29173304
Drug: Prednisolone/prednisone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone/prednisone (1.5 mg/kg/d for 1 day, followed by 1 mg/kg/d on days 2‐5)
Trial: 25537065
Drug: Sport goggles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sport goggles (G)
Trial: 21349458
Drug: Heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin + glycoprotein IIb/IIIa inhibitor
Trial: 17209059
Drug: 6 weekly
RxNorm normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weekly 2-CdA infusions
Trial: 16942627
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) twice daily sessions
Trial: 16942627
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) once daily sessions
Trial: 8754291
Drug: FMLP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMLP solution
Trial: 1941404
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus infusion of 10% calcium gluconate
Trial: 1941404
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus infusion of 5% calcium gluconate
Trial: 1941404
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus infusion of calcium gluconate (both 5% and 10%)
Trial: 7009993
Drug: Intrapleural BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural BCG immunotherapy
Trial: 28407726
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) plus active Attention Bias Modification Therapy (ABMT)
Trial: 28407726
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) plus placebo Attention Bias Modification Therapy (ABMT)
Trial: 26329852
Drug: Pre-cooling for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-cooling for 2 min before plain lidocaine injection
Trial: 26329852
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine injection
Trial: 24009042
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg)
Trial: 20972299
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of antibiotics (48 to 96 hours)
Trial: 20972299
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of antibiotics
Trial: 19260871
Drug: FENO guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO guided therapy
Trial: 19260871
Drug: Standard asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard asthma therapy
Trial: 15479681
Drug: Prebiotic carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic carbohydrates (7.5 g of oligofructose and 7.5 g inulin)
Trial: 11777121
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy (SEG)
Trial: 7951548
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment in untreated patients with low thyroid CT number
Trial: 7951548
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment in patients with normal thyroid CT number prior to therapy
Trial: 3038156
Drug: Oral nafazatrom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nafazatrom (Bay g6575, 2 X 3 g)
Trial: 31811542
Drug: Myofunctional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofunctional therapy support program (MTSP) for 12 weeks
Trial: 31811542
Drug: One education
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One education session of myofunctional therapy (control)
Trial: 22867771
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections of insulin (MDI)
Trial: 21982167
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol and remifentanil (PR group)
Trial: 15680096
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (open reduction and internal fixation using a standard lateral approach)
Trial: 15680096
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (ice and elevation)
Trial: 12067850
Drug: DCA infusion
RxNorm normalized name: DCA
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCA infusion (100 mg/kg body wt)
Trial: 12067850
Drug: Control (normoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normoxic breathing and saline infusion)
Trial: 9876731
Drug: Nizatidine 100
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine 100 mg intravenously
Trial: 7900703
Drug: Continuous fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous fluorouracil infusion (FUcont)
Trial: 2612552
Drug: Predictive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive warfarin maintenance dosing technique
Trial: 2612552
Drug: Empirical dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical dosing method
Trial: 11938803
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs (CD) for invigorating Spleen to remove dampness, activating blood circulation to eliminate Turbid
Trial: 1383924
Drug: MOP chemotherapy
RxNorm normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MOP chemotherapy
Trial: 1383924
Drug: MOP/ABVD chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOP/ABVD chemotherapy
Trial: 3905463
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg) in addition to routine insulin treatment
Trial: 25486269
Drug: Levodopa equivalent
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa equivalent daily dose
Trial: 25481367
Drug: Caffeine administration
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine administration (conditional vs deceptive)
Trial: 23560727
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily for 1 week
Trial: 21493022
Drug: Estrogen therapy-control
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy-control (ET-CO)
Trial: 19820441
Drug: Natalizumab induction
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab induction therapy (12 weeks)
Trial: 19820441
Drug: Natalizumab maintenance
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab maintenance therapy (48 weeks post-induction)
Trial: 9336321
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alcohol (0.8 g/kg) and cocaine (100 mg)
Trial: 9336321
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alcohol and cocaine
Trial: 2879734
Drug: Urapidil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 15 mg i.v.
Trial: 2879734
Drug: Urapidil 30
RxNorm normalized name: urapidil 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 30 mg i.v.
Trial: 2879734
Drug: Propranolol 5
RxNorm normalized name: propranolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 5 mg i.v. (positive control)
Trial: 26665553
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) alone
Trial: 26665553
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Intravitreal bevacizumab + macular photocoagulation)
Trial: 12927315
Drug: estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol 2 mg/day + cyproterone acetate 1 mg/day in a cyclic sequential regimen
Trial: 12927315
Drug: estradiol hemihydrate
RxNorm normalized name: Estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen
Trial: 12927315
Drug: estradiol hemihydrate
RxNorm normalized name: Estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen
Trial: 11009230
Drug: Oral mexiletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mexiletine (up to 900 mg/d)
Trial: 8725471
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (160 mg per day in two divided doses)
Trial: 28404110
Drug: Ombitasvir (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin for 12 weeks
Trial: 24965536
Drug: Catumaxomab plus
RxNorm normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catumaxomab plus prednisolone (25 mg intravenous premedication)
Trial: 22692377
Drug: S-ketamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (20 mg/h for 2 h)
Trial: 18506154
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg daily (n = 29)
Trial: 18506154
Drug: AEGR-733 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEGR-733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks, and 10 mg daily for the last 4 weeks (n = 28)
Trial: 18506154
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg daily and AEGR-733 with dose titration (n = 28)
Trial: 9712245
Drug: Specialists in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialists in gastrointestinal medicine
Trial: 7749424
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg body weight)
Trial: 28681744
Drug: Maintained levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maintained levodopa dose (Group 1, n = 66)
Trial: 28681744
Drug: Reduced levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reduced levodopa dose by 15-25% (Group 2, n = 41)
Trial: 28681744
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after LCE administration
Trial: 24366725
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 0.5% (15 mg test dose + 50 mg)
Trial: 23031632
Drug: Silymarin cream
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin cream (0.1) applied twice daily for 4 weeks
Trial: 23031632
Drug: Silymarin cream
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin cream (0.2) applied twice daily for 4 weeks
Trial: 23417317
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 4 weeks
Trial: 20415160
Drug: Self-controlled concurrent
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-controlled concurrent feedback
Trial: 20415160
Drug: Imposed concurrent
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imposed concurrent feedback (yoked group)
Trial: 20415160
Drug: No concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No concurrent feedback (control group)
Trial: 15356071
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (transdermal estradiol 50 microg and micronized progesterone 100 mg/d)
Trial: 11594636
Drug: Balance training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance training in group, twice a week for eight weeks
Trial: 2675962
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + CS + CL
Trial: 2675962
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + CL
Trial: 2675962
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + CS + CO + CL
Trial: 9062854
Drug: G
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G
Trial: 28386739
Drug: Articaine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 60 mg with fentanyl 10 µg (group AF10)
Trial: 28386739
Drug: Articaine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 60 mg with fentanyl 20 µg (group AF20)
Trial: 28386739
Drug: Plain articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain articaine 60 mg with saline (group AF0)
Trial: 28386739
Drug: Fentanyl 20
RxNorm normalized name: fentaNYL 200 mcg buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 20 µg (group AF20)
Trial: 25361738
Drug: Heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treatment in Han patients
Trial: 23836249
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 80 mg tobramycin twice daily for 12 months
Trial: 15533901
Drug: Soy intervention
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy intervention (two daily servings of soy foods containing approximately 50 mg of isoflavones)
Trial: 11533326
Drug: Single-dose ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ferrous sulfate drops (40 mg elemental iron once daily)
Trial: 11533326
Drug: 3-times-daily ferrous
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-times-daily ferrous sulfate drops (40 mg elemental iron total per day)
Trial: 11533326
Drug: Single-dose ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ferrous sulfate drops
Trial: 11533326
Drug: 3-times-daily ferrous
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-times-daily ferrous sulfate drops
Trial: 2223330
Drug: Alfentanil 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 50 micrograms kg‐1 followed by an infusion of 50 micrograms kg‐1 h‐1 and propofol infusion
Trial: 2223330
Drug: Clonidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.6 mg added to premedication
Trial: 6989245
Drug: Multidose intravenous
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose intravenous sodium cephalothin
Trial: 6989245
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous sodium cephalothin
Trial: 6989245
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral metronidazole
Trial: 31407871
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil orally once daily for 12 weeks
Trial: 28583031
Drug: Bortezomib dose
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib dose intensity ≥4.6 mg/m2/cycle
Trial: 28583031
Drug: Bortezomib dose
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib dose intensity <4.6 mg/m2/cycle
Trial: 25456560
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of 3.7 to 55.7 mg of samidorphan
Trial: 25456560
Drug: Multiple ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of 10 or 20 mg of samidorphan for 7 days
Trial: 19755964
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A (immunosuppressed patients)
Trial: 19755964
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group B (non-immunosuppressed patients)
Trial: 19755964
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group C (healthy controls)
Trial: 19755964
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A
Trial: 18616088
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate (one tablet three times daily) for 4 weeks
Trial: 18616088
Drug: Betahistine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (12 mg betahistine dimesylate, one tablet three times daily) for 4 weeks
Trial: 18616088
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate
Trial: 16139582
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation plus treatment as usual (VNS+TAU)
Trial: 3971683
Drug: Oral narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral narcotic analgesics plus ibuprofen 400 mg four times daily
Trial: 3971683
Drug: Oral narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral narcotic analgesics alone (placebo)
Trial: 29741912
Drug: Standardized capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized capsules of Stachys lavandulifolia
Trial: 17647055
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of chili powder along with antibiotics and analgesics
Trial: 17647055
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and analgesics alone
Trial: 15999594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy alone or in combination with hormone therapy
Trial: 15999594
Drug: Standard hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hormone therapy
Trial: 15999594
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy and chemotherapy
Trial: 9859533
Drug: Cefoxitin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 3 x 1 g (14 subjects)